Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
Sign Up to like & getrecommendations! Published in 2018 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2018.02.088
Abstract: BACKGROUND The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that T-cell-depleting agents should be used only for kidney transplant (KT) recipients at high immunologic risk. However, the effects of thymoglobulin induction therapy in low-immunologic… read more here.
Keywords: risk; induction therapy; immunologic risk; therapy ... See more keywords